Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy
Hydration Intervention to Address Dehydration Associated With Use of GLP-1 Based Medications
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years to 60 Years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
In plain language
This 17-week study tests whether drinking more fluids can reduce side effects and help people stay on GLP-1 RA medicine. It is for adults ages 18–60 who were prescribed this medicine within the past week. The study also checks how well people can follow the study plan.
This is a 17 - week study consisting of a one - week run - in period and a 16 - week intervention. The 16 - week pilot interventions aims to increase hydration in those beginning GLP - 1 RA therapy. Investigators aim to increase hydration to potentially decrease side effect severity, amount of side effects, and drug discontinuation associated with GLP - 1 RA therapy. The investigators are piloting to assess feasibility and preliminary efficacy of the intervention through examining participant retention, participant feedback, researcher and participant adherence to protocols, impact on hydration biomarkers, and participant reported GLP - 1 RA side effects.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Who can join
- Age 18–60.
- Prescribed a GLP-1 RA medicine within the past week.
- Fluent in English.
- Willing to follow the study plan.
Who can't join
- Younger than 18 or older than 60.
- Not taking a GLP-1 RA medicine.
- Taking a GLP-1 RA medicine for more than one week.
- Not fluent in English.
- Pregnant or planning to become pregnant during the study.
- Unwilling to follow the study plan.
- Have a heart implant, such as a device placed in the heart.
Simplified for readability. The official criteria below are what the study team uses.
Official eligibility criteria
Inclusion Criteria: * Adults aged 18-60 * Recently prescribed a GLP-1RA (within one week of prescription) * Fluent in English * Willing to complete the study protocol Exclusion Criteria: * Children and adults \> 60 years of age * Those not taking a GLP-1RA * Those who have been on a GLP-1RA longer than one week * Not fluent in English * Those who are pregnant or planning on becoming pregnant during the duration of the study * Unwilling to comply with study protocol * People with cardiac implants
Study sites (1)
NY
- State University of New York at Buffalo, South Campus · Buffalo, NY 14214Hannah E Kolpack, BS · Study contact · (716) 829 - 5820 · hkolpack@buffalo.eduKatherine N Balantekin, PhD, RD · Principal investigatorElizabeth G Mietlicki-Baase, PhD · Principal investigatorLeonard H Epstein, PhD · Principal investigatorMore trials in Buffalo